Oncology Pharma Inc (OTCMKTS: ONPH) has been persistent in its investigation and work, studying and applying partnership between its interests in treatment, distribution, and trial knowledge amongst its approved produces.
The company plan is in the early phases of appraisal
In the early phases of appraising the work and inspecting openings between its approved Intellectual Properties’ synergistic values and relating its know-how towards progressing the approved IP, it has NanoSmart, Sybleu, Regen Biopharma, and Ribera Solutions.
The company considers that it can benefit within frugality of scale, and new IP can be shaped through a combination of treatments and distribution contrivances. In addition to seeking ways to improve value with its current collection of possessions, Oncology Pharma has begun deliberations within its system to classify important players to implement its objectives. Being able to yield its intellectual properties would be a critical constructing block in its objective towards growth.
Oncology Pharma will further be looking into possibly exploiting a solitary CRO (Clinical Research Organization) in combination with its know-how within the company.
Oncology Pharma to release White Paper charting five Pioneering Methods to advance patient commitment in Scientific Trials
Oncology Pharma is releasing a White Paper charting five ground-breaking ways to advance patient commitment in scientific trials. The five critical points in the White Paper: Fitness Knowledge, Patient Caretaker Service, Pilot Support Public, Easy-to-use User Interface, and Endowing with data.
Oncology Pharma is delighted to advance this technology and looks forward to utilizing the platform for its studies involving our licensed IP utilizing its features and increasing engagement and efficiencies.
Connect2Med is a patient commitment and preservation platform intended to improve the scientific trial experience for both patients and suppliers. Connect2Med, patrons, CROs, and sites have a place for clues, or people in their records, to ‘live’ in an online public. The platform provides a secluded, safe space where people absorbed in or employed in scientific trials have a harmless, closed community they can join that delivers reliable information and sympathetic connections to help them on their trip.